FIELD: immunology.
SUBSTANCE: there are presented isolated antibodies able to specifically bind IL-33. Invention also covers a nucleic acid molecule, a composition and a cell. What is also described is a method of treating a disorder which is susceptible to inhibiting IL-33.
EFFECT: present invention can find further application in therapy of various conditions, in particular autoimmune diseases and cancer.
25 cl, 9 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEUTRALIZING MONOCLONAL HUMAN ANTI-INTERLEUKIN-33 ANTIBODIES | 2014 |
|
RU2709722C1 |
| ANTIBODIES AGAINST IL-33, COMPOSITIONS, METHODS AND THEIR APPLICATION | 2017 |
|
RU2740309C2 |
| ANTIBODIES DIRECTED AGAINST IL-17 | 2011 |
|
RU2595385C2 |
| IL-1beta-BINDING ANTIBODIES AND FRAGMENTS THEREOF | 2006 |
|
RU2518295C2 |
| NEW FORM OF IL33, MUTATED FORMS OF IL33, ANTIBODIES, ANALYZES AND METHODS OF USING THEM | 2016 |
|
RU2736299C2 |
| ANTIBODIES DIRECTED TO PROTEIN OF PROGRAMMED DEATH OF CELL-1 (PD-1) | 2014 |
|
RU2723050C2 |
| ANTIBODIES AGAINST HUMAN IL33R AND USE THEREOF | 2012 |
|
RU2597288C2 |
| ANTIBODIES SPECIFIC FOR LIGAND 1A, SIMILAR TO TUMOR NECROSIS FACTOR, AND THEIR COMPOSITIONS AND APPLICATION | 2014 |
|
RU2708140C1 |
| ANTIBODIES DIRECTED AGAINST THE INTERLEUKIN 36 (IL-36R) RECEPTOR | 2016 |
|
RU2745898C2 |
| ANTI-IL-17F ANTIBODIES AND METHODS FOR USE THEREOF | 2010 |
|
RU2605318C2 |
